**WHAT IS THE TITLE OF THE STUDY?**
Efficacy and Safety of ADS-5102 (amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia in Parkinson’s Disease Patients (EASE LID Study)

**WHAT IS THE PURPOSE OF THE STUDY?**
The purpose of the study is to test the safety and effectiveness of an investigational medication, amantadine HCl Extended Release Capsules, in patients who have troublesome levodopa induced dyskinesia (involuntary jerking and twisting). Amantadine IR (Immediate Release) is currently approved by the FDA for the treatment of Parkinson’s disease. This study will test the safety and effectiveness of amantadine HCl extended release capsules to determine if it can reduce levodopa induced dyskinesias (involuntary jerking and twisting) for Parkinson’s disease patients. We want to find out what effects, good and/or bad, it has on you and your Parkinson’s disease.

**WHO IS NEEDED?**
To pre-qualify for this study, the participant must:
- Be 30-85 years old
- Be diagnosed with idiopathic Parkinson’s disease
- Be taking levodopa at least 3 times per day, for at least the last 30 days
- Be experiencing levodopa induced troublesome dyskinesias (involuntary jerking/twisting)
- Not have taken amantadine within the last 30 days
- Have no history of Deep Brain Stimulation (DBS)
- Additional criteria apply

**WHAT IS INVOLVED IF I PARTICIPATE?**
**Duration:** There are up to 11 office visits over a period of approximately 29 weeks. At the end of this study, you may have the option to transition to the **EASE LID 2 Study**, which is a long-term open label study of the same drug, lasting approximately 57 weeks and includes 9 office visits.

**Tests/procedures:** Physical and Neurological exams, an ECG test to trace heart rhythm, questionnaires, blood draws, urine tests, and periodic input into a diary. The study drug is administered in a capsule form, which you swallow, taken at bedtime.

**Risks:** Risks will be discussed with volunteers as part of the informed consent process.

**Benefits:** Participation might help future patients with PD.

**Compensation:** Volunteers will be compensated for each completed visit.

**WHO IS THE PRINCIPAL INVESTIGATOR (DOCTOR)?**
Susan Criswell, MD

**WHERE WILL THE STUDY TAKE PLACE?**
Washington University School of Medicine
Contact Name: Karen McDonell 314-747-0514 or mcdonellk@neuro.wustl.edu